P676 Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.

shown in 25 CD (69.4%) and 19 UC (57.6%) patients. The over-all rate of loss of response was 30.4% in CD and 34.8% in UC at week 54. High CRP level at week 30 and low CT-P13 trough level at week 14 predicted to loss of response in CD. None of the examined parameters were predictive to the therapeutic outcome in UC. No difference was observed regarding the clinical outcome at week 54 between anti-TNF naïve patients and patients previously treated with an anti-TNF agent. Conclusions: This study confirmed the long-term efficacy and safety of CT-P13 therapy IBD. However, lower response rate was shown at week 54 in UC than in CD. High CRP and low CT-P13 trough levels were predictive to treatment outcome in CD but not in UC. Background: Adalimumab (ADA) and infliximab (INF) are approved for treating patients with ulcerative colitis (UC) who have failed con-ventional therapy. Research comparing the effectiveness of these ther-apies following induction is limited. We compared the real-world effectiveness of initiating ADA versus INF among patients in the early weeks of treatment. Methods: 170 randomly selected physicians in the U.S. retrospec-tively abstracted clinical and healthcare resource utilization information from the charts of adults with UC initiating ADA or INF therapy between 1 Oct 2012 and 30 Apr 2014. Patients were anti-TNF naïve, did not have a Crohn’s Background: We aimed to evaluate the toxicity profile of the AZA. We obtained the information from our 17 years old IBD registry. We also wished to compare the parameters of these current information with our a decade old previously registered IBD data. Methods: We reviewed the charts of our IBD outpatient clinic from 1999 to 2016. (264 F and M a mean of dosage pts (4%) continued with dose reduction. AZA to leukopenia, neutropenia GSF drug drug Background: CT-P13 was the first Infliximab biosimilar approved in Europe. Several studies confirmed the efficacy, safety, and inter-changeability of CT-P13 in patients with immune mediated inflammatory disorders, but there are limited reports on clinical outcomes in patients with inflammatory bowel disease (IBD) requiring dose escalation. Methods: IBD patients that required dose escalation during treatment with Remicade, or were previously under escalated dosing, were switched to biosimilar CT-P13. Escalation was defined as in-creased dose ≥ 7.5 mg/kg/8 weeks and/or a shortening of the interval ≤ 6 weeks. Disease activity was evaluated with the Crohn’s Disease Activity Index (CDAI) for Crohn’s Disease (CD) and full Mayo Score (including endoscopy) for Ulcerative Colitis (UC). Clinical and biological vari-ables were analyzed before the first infusion of CT-P13 and after 24 weeks of treatment. Results: Thirty patients received escalated CT-P13 dose (18 CD and 12 UC), 53% men, median age 42 years (IQR 22–71). 9/30 patients (30%) were previously intensified with Remicade and switched to CT-P13 maintaining the same dose and 21/30 patients (70%) were switched at the time of dose escalation. Median time with Remicade treatment before switching to CT-P13